Patent for License:

A Plasmid construct for Testing the Resistance of HIV-1 Subtype C virus    

A Plasmid construct for testing the resistance of HIV-1 Subtype C virus effectiveness of chemical compounds to inhibit HIV-1 replication in-vitro

Overview

The object of this technology is to propose a plasmid containing the genome of Human Immunodeficiency Virus type 1 (HIV-1) for effectual testing of effectiveness of chemical compounds to inhibit HIV-1 replication in-vitro. The technology suggest recombinant plasmid pPS4.3HSAR-E; comprising HIV-1 genome with defective envelope gene and mutated gag-pol gene wherein Xmal and SacII restriction enzyme sites have been introduced on either side of reverse transcriptase (RT) gene inserted in a plasmid vector. It also suggest that plasmid containing genome of HIV-1 from which RT gene can be easily removed and replaced with RT of any other HIV-1 isolate. It also offers the method for constructing the plasmid for effective testing.

The viral genome is mounted onto a carrier DNA molecule called a plasmid. This plasmid when transfected in an eukaryotic cell expresses the proteins of virus on the surface of the cell which can be easily visualized either under the immunofluorescent microscope or by flowcytometer or Enzyme Linked Immunosorbent Assay (ELISA). The expression of viral proteins on the cell surface is inhibited by antiretrovirals.

Primary Application of the Technology

AIDS / HIV positive

The Problem Solved by the Technology

- The object of this technology is to propose a plasmid containing the genome of Human Immunodeficiency Virus type 1 (HIV-1) for effectual testing of effectiveness of chemical compounds to inhibit HIV-1 replication in-vitro.

How the Technology Solves the Problem

The technology suggest recombinant plasmid pPS4.3HSAR-E; comprising HIV-1 genome with defective envelope gene and mutated gag-pol gene wherein Xmal and SacII restriction enzyme sites have been introduced on either side of reverse transcriptase (RT) gene inserted in a plasmid vector. It also suggest that plasmid containing genome of HIV-1 from which RT gene can be easily removed and replaced with RT of any other HIV-1 isolate. It also offers the method for constructing the plasmid for effective testing.

Competitive Advantage

The object of this technology is to propose a plasmid containing the genome of Human Immunodeficiency Virus type 1 (HIV-1) for effectual testing of effectiveness of chemical compounds to inhibit HIV-1 replication in-vitro.

Comments on Deal Structure, Potential Terms and Restrictions

Available for licensing; Buyer-side commission fee